Novartis Encouraged by its New Multiple Sclerosis Drug FTY72
Novartis, a drug company, has recently released its quarterly report on earnings and the future looks bright. This can be in part thanks to the recent approval for FTY720, a drug that combats multiple sclerosis. The company reports earnings of “free cash flow” at about $2.4 million dollars.
Multiple Sclerosis (MS) is, according to WebMd, “is a disease that affects the brain and spinal cord resulting in loss of muscle control, vision, balance, and sensation (such as numbness). With MS, the nerves of the brain and spinal cord are damaged by one's own immune system.” One of the most insidious parts of this disease is that the symptoms come and go. Sometimes a person can’t walk. Then the next day, they can walk but cannot see.
While there have been many improvements in the treatment of MS, it remains incurable at this time. Patients can compare various treatment options, including medication and physical therapy, to see what will work best with them by clicking here http://www.webmd.com/relapsing-ms/consider-treatment
In late June, Novartis received approval for the FTY720 drug from the Food and Drug Administration (FDA) in the United States. This approval means the difference in millions of people’s lives with MS. This drug is reportedly able to lengthen the time between relapsing MS events. While a surgical option goes into clinic trials, the FTY720 may make the wait more bearable for MS patients who hope the surgery proves successful. The results of trials published in the New England Journal of Medicine reports that FTY720 not only works, but works better than current medication treatment options.
As the company moves forward with other successful drugs in addition to the FTY720, many investors are buying stock. The share price is as of publication $53.20. With market share in animal health, vision health, vaccines, oncology, and more, the future is definitely looking bright for Novartis.